Healthcare Global Enterprises Ltd Q1 FY27 Earnings Analysis

- FY26 revenue growth was 15% year-on-year, with broad-based growth across regions. - Q4 growth impacted by paring down low-margin business and Middle East conflict affecting medical value travel; normalization expected in coming quarters. - Medium-term revenue growth estimate remains close to 15%. - Patient volumes increased by 12% with a 3% improvement in average revenue per patient. - Growth driven by better center utilization, clinical talent additions (23 oncologists added in Q4), and expansion initiatives like North Bangalore and Whitefield. - Expansion via brownfield projects (adding 200+ beds over 24 months in multiple cities) and selective greenfield projects in 10-12 cities under evaluation. - Digital and sales acceleration efforts (doubling Day-Care centers) to support growth. - Potential for inorganic growth through acquisitions, though no major updates currently. - Existing hospitals expected to contribute 75-80% of growth over next 2-3 years through capacity expansion and utilization improvements.

- HCG targets around 15% revenue growth over the medium term, supported by 12% patient volume growth and 3% improvement in average revenue per patient (ARPP). - The company focuses on profitable, broad-based growth with margin expansion and improving returns rather than merely chasing top-line growth. - Adjusted EBITDA margins improved by 70 basis points to 18.5% in FY26, and management expects further margin expansion driven by operating leverage, better utilization, throughput optimization, and cost discipline. - Pre-tax ROCE improved to 14% in FY26, with a medium-term target of around 20% ROCE within next 4-5 years. - Expansion plans include adding about 1,000 beds by FY30 (400 greenfield, 600 brownfield), bolstering growth and returns. - Management is confident of continuing EBITDA margin improvement, aiming for likely further 100 basis points expansion by FY27. - Cash flow conversion remains strong (~75%-87%), supporting sustainable earnings growth and debt reduction.

- Near-term capex focused on brownfield expansions with faster ramp-up and better returns. - Approximately 200+ beds to be added over the next 24 months: 75 in Cuttack, 30 in Ranchi, 50 in Vizag, 20+ in Bhavnagar. - Selective greenfield expansions planned, including North Bangalore and Whitefield facilities; evaluation ongoing for 10-12 additional cities (e.g., Pune, Surat, Coimbatore, Nellore, Lucknow, Jalandhar). - Average brownfield bed addition cost estimated at INR 45 lakh per bed; INR 90-100 crore CAPEX for 200 beds. - Capital raised INR 425 crore rights issue strengthens financial foundation for capacity expansion, clinical infrastructure upgrades, and technology investments. - Asset-light model adopted for new technology like MR-Linac on a pay-per-use basis. - Strategic divestment of non-core Milann fertility business to focus capital and management bandwidth on core oncology platform. - Internal target net debt to EBITDA ratio of 2.5x maintained to ensure prudent capital allocation.

- The company successfully completed a rights issue of INR 425 crore, which has strengthened its financial foundation and provided greater flexibility for investments. - The capital raised positions the company well for capacity expansion, clinical infrastructure upgrades, technology investments, and selective growth opportunities. - Management intends to maintain a disciplined, return-focused approach to capital allocation. - There is no specific mention of any immediate or planned new fundraising through debt or equity beyond the recently completed rights issue. - The company has maintained an internal net debt to EBITDA target ceiling of 2.5x to allow headroom for expansion while managing leverage prudently. - Ongoing debt reduction is planned as the company aims to reduce interest costs and optimize leverage with current funds.

The provided transcript does not mention any details regarding the current or expected order book or pending orders for HealthCare Global Enterprises Limited. The discussion primarily focuses on operational performance, expansion plans, financial results, margins, growth strategies, and new facilities such as the North Bangalore facility with the MR-Linac. No references to order book status or pending orders are made in the transcript.